Moreover, some studies also indicated that a high level of serum SDF-1 was associated with an increased risk of poor functional outcome and animal studies reported that the SDF-1 antagonist AMD3100 significantly improved functional recovery after stroke [8–10]. Here, CXCL12 is linked to stroke disorder.